TNF Inhibitors Such as INmune Bio Inc.’s (NASDAQ: INMB) XPro1595 May Reduce the Risk of Alzheimer’s Development, Report Suggests

July 17, 2019 10:28:33
  • Research indicates that anti-inflammatory medications have the power to prevent the onset and control the symptoms of Alzheimer’s disease
  • The link between inflammatory processes and Alzheimer’s has long been established; companies like INmune Bio are working to further the research and develop safe and effective drugs based on disrupting this mechanism
  • INmune Bio has received a $1 million grant from the Alzheimer’s Association to bring its lead drug candidate, XPro1595, to the clinical testing stage

Could tumor necrosis factor-alpha (TNF-α) inhibition be the next big thing in the world of Alzheimer’s disease (AD) treatment? A detailed Washington Post report focuses on research carried out by a Pfizer Inc. (NYSE: PFE) team ( According to the researchers, one of the company’s rheumatoid arthritis anti-inflammatory drugs appeared to reduce the risk of Alzheimer’s disease development by as much as 64 percent.

Pfizer researchers went through thousands of insurance claims in 2015, reaching the conclusion that the rheumatoid arthritis pharmaceutical had such an effect on AD. Carrying out a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office